Axsome Q3 2022: First Sunosi revenue $16.8M, Auvelity launched, net loss $44.8M

Axsome Therapeutics, Inc.

2022-Q3 EPS reported -$3.17 revenue$25,665,578

Sunosi U.S. net sales $16.8M (first reported by Axsome); total revenues $16.8M vs $0 prior year.
Net loss $44.8M ($1.07/share) vs $34.9M ($0.93) in Q3 2021; R&D $14.9M, SG&A $40.9M.
Cash $227.5M (vs $86.5M Dec 2021); expects cash to fund operations into 2025.
Auvelity launched Oct 20, 2022 for MDD; field force with prior psychiatry experience engaging prescribers.
Pipeline: AXS-07 NDA resubmission Q3 2023; AXS-05 ACCORD topline Q4 2022; solriamfetol ADHD trial Q4 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Axsome Therapeutics, Inc. reported financial results for the three months ended September 30, 2022.

Period: the three months ended September 30, 2022
Result: reported results

Exact text from the filing

On November 7, 2022, Axsome Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended September 30, 2022 and provided an update on the Company’s operations.

View on SEC.gov

Browse all earnings releases →

Axsome Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-022315

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.